GlaxoSmithKline (GSK) has partnered with Relation Therapeutics in a research collaboration worth up to $110 million. The partnership aims to utilize artificial intelligence in drug discovery by generating large-scale datasets on human cell responses to genetic changes and drug interventions. This data will be used to train AI models, potentially accelerating the development of new treatments. The collaboration builds on existing work between the two companies in AI-assisted drug discovery. This investment highlights the growing importance of biological data in the development of AI-driven pharmaceutical research.